Literature DB >> 16678584

Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases.

Zhifu Sun1, Marie-Christine Aubry, Claude Deschamps, Randolph S Marks, Scott H Okuno, Brent A Williams, Hiroshi Sugimura, V Shane Pankratz, Ping Yang.   

Abstract

OBJECTIVE: Our objective was to determine whether histologic grade independently contributes to the prognosis of non-small cell lung cancer.
METHODS: A total of 5018 hospital-based patients diagnosed from 1997 to 2003 and 712 population-based patients diagnosed from 1984 to 2003 were followed up through the end of 2004. The effect of histologic grade on postdiagnosis survival or postresection recurrence was evaluated by Cox proportional hazards models. Relative risks (RR) were estimated by comparing undifferentiated, poorly differentiated, and moderately differentiated carcinoma with well-differentiated carcinoma.
RESULTS: Histologic grade was significantly associated with survival after adjustment for the effects of age, gender, smoking history, tumor stage, histologic cell type, and treatment modality. Patients with undifferentiated carcinoma had an 80% elevated risk of death (RR = 1.83; 95% confidence interval [CI], 1.4-2.4) compared with those with well-differentiated carcinoma; 70% and 40% elevated risks were observed for patients with poorly and moderately differentiated carcinoma, respectively (RR, 1.7 [1.5-2.0] and 1.4 [1.2-1.6]). Similar results were observed for 718 incidence cases in which the relative risks were 1.6 (1.1-2.2) and 1.4 (1.0-1.9) for poorly/undifferentiated carcinoma and moderately differentiated carcinoma, respectively. Patients with less-differentiated carcinoma after tumor resection had a higher risk of recurrence, with adjusted hazard ratios of 2.1 (95% CI: 1.4-2.9) and 1.4 (1.0-1.9) for poorly/undifferentiated and moderately differentiated carcinoma compared with well-differentiated carcinoma.
CONCLUSIONS: Histologic grade has significant prognostic value for survival of patients with non-small cell lung cancer. Histologic grade may provide useful information in defining the aggressiveness of tumors and should be considered as an independent factor affecting survival beyond TNM staging.

Entities:  

Mesh:

Year:  2006        PMID: 16678584     DOI: 10.1016/j.jtcvs.2005.12.057

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  54 in total

Review 1.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification.

Authors:  Xiaohong Fan; Xueyan Zhang; Huimin Wang; Bo Jin
Journal:  Tumour Biol       Date:  2014-06

3.  Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients.

Authors:  Z Sun; J Chen; J Aakre; R S Marks; Y Y Garces; R Jiang; O Idowu; J M Cunningham; Y Liu; V S Pankratz; P Yang
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

4.  Reimagining T Staging Through Artificial Intelligence and Machine Learning Image Processing Approaches in Digital Pathology.

Authors:  Kaustav Bera; Ian Katz; Anant Madabhushi
Journal:  JCO Clin Cancer Inform       Date:  2020-11

5.  Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts.

Authors:  Jennifer M Boland; Jason A Wampfler; Jin S Jang; Xiaoke Wang; Michele R Erickson-Johnson; Andre M Oliveira; Ping Yang; Jin Jen; Eunhee S Yi
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

6.  Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.

Authors:  Cassandra Johnson; Vernon S Pankratz; Ana I Velazquez; Jeremiah A Aakre; Charles L Loprinzi; Nathan P Staff; Anthony J Windebank; Ping Yang
Journal:  J Neurol Sci       Date:  2015-01-05       Impact factor: 3.181

7.  Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.

Authors:  Dong Xie; Mark S Allen; Randolph Marks; Gening Jiang; Zhifu Sun; Frances Nichols; Mingrui Zhang; Chang Chen; Marie-Christine Aubry; Aminah Jatoi; Yolanda I Garces; Aaron Mansfield; Dennis Wigle; Julian Molina; Claude Deschamps; Ping Yang
Journal:  Eur J Cardiothorac Surg       Date:  2018-06-01       Impact factor: 4.191

8.  Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.

Authors:  Ann M Moyer; Zhifu Sun; Anthony J Batzler; Liang Li; Daniel J Schaid; Ping Yang; Richard M Weinshilboum
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 9.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

10.  Porting a cancer treatment prediction to a mobile device.

Authors:  Tim Gegg-Harrison; Mingrui Zhang; Nan Meng; Zhifii Sun; Ping Yang
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.